



April 18, 2013 06:13 AM Eastern Daylight Time

Alitair Offers Patented IER Formulations with Intrinsic Abuse Deterrence Properties

MORRISTOWN, N.J.--([BUSINESS WIRE](#))--Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple respiratory product candidates in development, today provided additional details regarding its '617 patent, which will be offered at a sealed bid sale on May 24, 2013. The '617 patent covers ion-exchange resin (IER) formulations that have intrinsic abuse deterrence properties. Abuse deterrence is a critical success factor in the opioid pain market.

The Alitair '617 patent covers the use of ion-exchange resins in immediate-release and extended-release solid oral dosage forms. The patent covers formulations that are applicable to a wide range of drugs, including opioids. IER technology has significant abuse deterrence properties that make it difficult to smoke, snort, inhale, or inject opioid drugs. Crushing or grinding has no effect on these properties.

Because IER technology is the foundation of the Alitair '617 patent, its patented formulation features make it a very strong platform for pain products. Additionally, Alitair has filed a continuation-in-part with the USPTO which will further extend the IP of this platform.

The Alitair '617 patent will be sold at a sealed bid sale on May 24, 2013, at noon. Parties interested in bidding must sign a confidential disclosure agreement, which can be obtained from Chris Finn of Finn, Warnke, and Gayton by emailing cfinn@finnwarnkegayton.com or by calling 781-237-8840.

About Alitair Pharmaceuticals:

Alitair Pharmaceuticals, Inc. discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology, REA™, and other product candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com.

About Finn, Warnke & Gayton, LLP:

Joseph F. Finn, Jr. C.P.A., is the founding partner of Finn, Warnke & Gayton, LLP (www.finnwarnkegayton.com) Certified Public Accountants of Wellesley Hills, Massachusetts. For further information, please contact Chris Finn at 781-237-8840 or cfinn@finnwarnkegayton.com.

